JP2002145789A - Lipid peroxide inhibitor - Google Patents
Lipid peroxide inhibitorInfo
- Publication number
- JP2002145789A JP2002145789A JP2000335960A JP2000335960A JP2002145789A JP 2002145789 A JP2002145789 A JP 2002145789A JP 2000335960 A JP2000335960 A JP 2000335960A JP 2000335960 A JP2000335960 A JP 2000335960A JP 2002145789 A JP2002145789 A JP 2002145789A
- Authority
- JP
- Japan
- Prior art keywords
- lipid peroxide
- inhibitor
- peroxide inhibitor
- herbs
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、過酸化水素注射及
びオゾン療法等の血液殺菌療法、抗ガン治療並びにイン
フルエンザ治療等により正常細胞を損傷して発生する過
酸化脂質を低減させる過酸化脂質抑制剤に関する。[0001] The present invention relates to lipid peroxide suppression which reduces lipid peroxide generated by damaging normal cells by blood sterilization therapy such as hydrogen peroxide injection and ozone therapy, anticancer therapy, and influenza therapy. Agent.
【０００２】[0002]
【従来の技術】従来、人体等において、腫瘍細胞やウイ
ルス感染細胞が酸化に対して弱いことに着目し、過酸化
水素注射やオゾン注射のいわゆる酸素療法等が知られて
いる。これら酸素療法は、ヨーロッパやアメリカで約８
０年の歴史を持ち、１９１８年に流行したインフルエン
ザの死亡率を顕著に下げることができた。これら酸素療
法は、人体等に注入する過酸化水素やオゾンが体内や大
気に存在するものであるため、濃度が適性なら安全な療
法であるといえる。2. Description of the Related Art Conventionally, so-called oxygen therapy using hydrogen peroxide injection or ozone injection has been known, focusing on the fact that tumor cells and virus-infected cells are susceptible to oxidation in the human body and the like. These oxygen therapies are available in Europe and the U.S.
With zero years of history, it has significantly reduced the mortality rate of the influenza pandemic in 1918. These oxygen therapies can be said to be safe therapies if the concentration is appropriate, because hydrogen peroxide and ozone to be injected into the human body and the like are present in the body and the atmosphere.
【０００３】しかしながら、これら酸素療法には、副作
用として、過剰な酸素が発生して過酸化水素や活性酸素
等が正常細胞を損傷してしまい、有毒な過酸化脂質を発
生させることがある。また、化学的癌治療により発生す
る、重篤な副作用として知られている白血球数の低下や
脱毛等は、この過酸化脂質に起因すると考えられてい
る。ところが、体内に蓄積された過酸化脂質を、有効に
抑制するような製剤はなく、腫瘍細胞やウイルス感染細
胞等の治療には大きな課題があった。[0003] However, as a side effect of these oxygen therapies, excess oxygen is generated, and hydrogen peroxide and active oxygen may damage normal cells, thereby generating toxic lipid peroxide. Further, it is considered that the decrease in white blood cell count, hair loss, and the like, which are known as serious side effects caused by the chemical cancer treatment, are caused by the lipid peroxide. However, there is no preparation that effectively suppresses lipid peroxide accumulated in the body, and there has been a major problem in treating tumor cells, virus-infected cells, and the like.
【０００４】[0004]
【発明が解決しようとする課題】そこで、本発明は、上
記従来の事情に鑑み開発されたものであり、体内等に発
生した過酸化脂質を抑制することによって、脱毛や白血
球数低下といった症状を改善することが可能な過酸化脂
質抑制剤を提供することを目的としている。SUMMARY OF THE INVENTION Accordingly, the present invention has been developed in view of the above-mentioned conventional circumstances, and suppresses lipid peroxides generated in the body and the like to reduce symptoms such as hair loss and a decrease in the number of white blood cells. It is intended to provide a lipid peroxide inhibitor that can be improved.
【０００５】[0005]
【課題を解決するための手段】上述した目的を達成する
ため、本発明者らが鋭意検討した結果、複数種類のハー
ブに含まれる食物繊維がイオン交換能を有するため、体
内における電子の発生を促進することができ、発生した
電子によって過酸化脂質を効果的に抑制できるといった
知見を得るに至り、本発明を完成した。すなわち、本発
明に係る過酸化脂質抑制剤は、複数種類のハーブを含
み、イオン交換能を有する混合ハーブを有効成分として
含むものである。Means for Solving the Problems In order to achieve the above-mentioned object, the present inventors have conducted intensive studies. As a result, dietary fiber contained in a plurality of kinds of herbs has ion exchange ability, so that generation of electrons in the body is suppressed. The present inventors have obtained the finding that they can be promoted and lipid peroxide can be effectively suppressed by the generated electrons, thus completing the present invention. That is, the lipid peroxide inhibitor according to the present invention contains a plurality of types of herbs and a mixed herb having ion exchange ability as an active ingredient.
【０００６】また、本発明に係る過酸化脂質抑制剤は、
体内で−２００ｍＶ以下の電子を発生させることが好ま
しい。さらに、本発明に係る過酸化脂質抑制剤におい
て、上記混合ハーブは、タイム、ローズマリー、ウコ
ン、フェンネル、グレープ種子、シルクペプチド、蒲公
英及びエゾウコギから選ばれる少なくとも１種以上から
なることが好ましい。Further, the lipid peroxide inhibitor according to the present invention comprises:
It is preferable to generate electrons of -200 mV or less in the body. Further, in the lipid peroxide inhibitor according to the present invention, the mixed herb is preferably composed of at least one or more selected from thyme, rosemary, turmeric, fennel, grape seed, silk peptide, Gong Kim and Eleuthero.
【０００７】[0007]
【発明の実施の形態】以下、本発明に係る過酸化脂質抑
制剤を詳細に説明する。過酸化脂質抑制剤は、複数種類
のハーブを混合してなるものである。複数種類のハーブ
としては、イオン交換能を有する食物繊維を含有するも
のであればいかなるハーブを使用しても良い。使用可能
なハーブとしては、例えば、タイム、ローズマリー、ウ
コン、フェンネル、グレープ種子、シルクペプチド、蒲
公英及びエゾウコギを挙げることができる。特に、これ
らのハーブから少なくとも１種類以上を選択し、複数種
類のハーブを混合して使用する。BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, the lipid peroxide inhibitor according to the present invention will be described in detail. Lipid peroxide inhibitors are obtained by mixing multiple types of herbs. As the plurality of types of herbs, any herbs containing dietary fiber having ion exchange ability may be used. Usable herbs include, for example, thyme, rosemary, turmeric, fennel, grape seeds, silk peptide, Kumiko Hide and eleuthero. In particular, at least one or more kinds are selected from these herbs, and a plurality of kinds of herbs are mixed and used.
【０００８】具体的に、タイム、ローズマリー、ウコ
ン、フェンネル、グレープ種子、シルクペプチド、蒲公
英及びエゾウコギの全てを用いた場合、合計が１００重
量％となる範囲で、タイムが8〜12重量％、ローズマリ
ーが8〜12重量％、ウコンが8〜12重量％、フェンネルが
8〜12重量％、グレープ種子が8〜12重量％、シルクペプ
チドが8〜12重量％、蒲公英が8〜12重量％及びエゾウコ
ギが25〜35重量％となるように混合することが好まし
い。Specifically, when all of thyme, rosemary, turmeric, fennel, grape seed, silk peptide, kumikohide and eleuthero are used, the thyme is 8 to 12% by weight within a range of 100% by weight in total. 8-12% by weight of rosemary, 8-12% by weight of turmeric, fennel
It is preferable to mix them so that 8 to 12% by weight, grape seeds are 8 to 12% by weight, silk peptide is 8 to 12% by weight, Kumiko Hide is 8 to 12% by weight, and eleuthero is 25 to 35% by weight.
【０００９】また、この過酸化脂質抑制剤は、体内に投
与されると、ハーブに含まれる食物繊維により陽イオン
交換能が発揮され、体内に電子を発生させる。具体的に
は、過酸化脂質抑制剤は、体内において、−２００ｍＶ
以下の電子を発生させることが好ましい。−２００ｍＶ
以下の電子を発生させることによって、体内に蓄積され
た過酸化脂質をより効果的に抑制することができる。[0009] When the lipid peroxide inhibitor is administered to the body, the dietary fiber contained in the herb exerts a cation exchange ability to generate electrons in the body. Specifically, the lipid peroxide inhibitor is -200 mV in the body.
It is preferable to generate the following electrons. -200mV
By generating the following electrons, lipid peroxide accumulated in the body can be more effectively suppressed.
【００１０】過酸化脂質抑制剤は、これら複数種類のハ
ーブを、例えば、160℃で乾燥殺菌した後に混合し、そ
の後、製粉機で粉末状に加工し、粉末状の混合ハーブを
所定の形状に成形して製造することができる。[0010] Lipid peroxide inhibitors are obtained by drying and sterilizing these plural kinds of herbs at, for example, 160 ° C, and then mixing them. Then, the mixture is processed into a powder by a mill, and the mixed herbs in a powder form are formed into a predetermined shape. It can be manufactured by molding.
【００１１】本発明の過酸化脂質抑制剤は、腫瘍細やウ
イルス感染の化学的療法及び放射線療法等の副作用とし
て生ずる白血球数の低下や脱毛等の副作用症状を抑制す
る目的で使用される。なお、白血球数の低下や脱毛等の
副作用症状は、化学的療法及び放射線療法等によるもの
であるか否かは問わない。The lipid peroxide inhibitor of the present invention is used for the purpose of suppressing side effects such as a decrease in white blood cell count and hair loss which occur as side effects such as chemotherapy and radiation therapy of tumor cells and viral infections. In addition, it does not matter whether side effects such as a decrease in white blood cell count and hair loss are caused by chemotherapy, radiation therapy or the like.
【００１２】本発明の過酸化脂質抑制剤は、過酸化脂質
の蓄積に起因する症状、例えば、白血球数の低下や脱毛
を改善することができる。過酸化脂質抑制剤は、過酸化
脂質蓄積に起因する症状であればこれらに限定されず、
いかなる症状をも改善することができる。また、過酸化
脂質抑制剤は、上記症状のいずれか１種に対して、ある
いは複数種が合併した症状を改善することができる。The lipid peroxide inhibitor of the present invention can improve symptoms caused by accumulation of lipid peroxide, such as a decrease in the number of white blood cells and hair loss. Lipid peroxide inhibitors are not limited to these as long as they are symptoms caused by lipid peroxide accumulation,
Any symptoms can be improved. In addition, the lipid peroxide inhibitor can improve a symptom associated with any one of the above symptoms or a combination of a plurality of the above symptoms.
【００１３】ここで、過酸化脂質とは、体内において蓄
積されるものであり、例えば、血中過酸化脂質、生体膜
過酸化脂質等を例示することができる。なお、体内に蓄
積された過酸化脂質は、従来より公知の手法を用いて測
定することができる。例えば、過酸化脂質濃度は、ＴＢ
Ａ、高速液体クロマトグラフィー、酵素法、ヨード測
定、比色、電位差滴、ガスクロマトグラフィー質量分析
といった手法を用いて測定することができる。Here, the lipid peroxide is accumulated in the body, and examples thereof include blood lipid peroxide, biological membrane lipid peroxide and the like. The lipid peroxide accumulated in the body can be measured using a conventionally known method. For example, the lipid peroxide concentration may be TB
A, High-performance liquid chromatography, enzymatic method, iodine measurement, colorimetry, potentiometric drop, gas chromatography mass spectrometry can be used for measurement.
【００１４】本発明の過酸化脂質抑制剤は、経口、非経
口投与のいずれでも可能であるが、好ましくは経口投与
である。経口投与に際して、過酸化脂質抑制剤は、錠剤
状、顆粒状、カプセル状及び粉末状等いかなる形状であ
ってもよい。過酸化脂質抑制剤の投与量は、患者の年
齢、症状により適宜選択することができる。有効投与量
は、１日につき体重1kgあたり5.5mg〜17.5mgの範囲で選
ばれる。あるいは、患者あたり400〜600mg/body、好ま
しくは600〜800mg/body、さらに好ましくは800〜1200mg
/bodyの投与量を選ぶことができる。しかしながら、本
発明の過酸化脂質抑制剤はこれらの投与量に制限される
ものではない。The lipid peroxide inhibitor of the present invention can be administered orally or parenterally, but is preferably administered orally. For oral administration, the lipid peroxide inhibitor may be in any form, such as tablet, granule, capsule and powder. The dose of the lipid peroxide inhibitor can be appropriately selected depending on the age and symptoms of the patient. The effective dose is selected in the range of 5.5 mg / kg to 17.5 mg / kg of body weight per day. Alternatively, 400-600 mg / body, preferably 600-800 mg / body, more preferably 800-1200 mg per patient
You can choose the dose of / body. However, the lipid peroxide inhibitor of the present invention is not limited to these dosages.
【００１５】また、投与時期としては、過酸化脂質の蓄
積時期の前後を問わず投与してもよく、あるいは白血球
の減少或いは脱毛が予測される時に投与してもよい。本
発明の過酸化脂質抑制剤は、常法にしたがって製剤化す
ることができ（Remington's Pharmaceutical Science,
latest edition, Mark Publishing Company,Easton,米
国）、医薬的に許容される担体や添加物を共に含むもの
であってもよい。The administration may be performed before or after the accumulation period of lipid peroxide, or may be administered when a decrease in leukocytes or hair loss is predicted. The lipid peroxide inhibitor of the present invention can be formulated according to a conventional method (Remington's Pharmaceutical Science,
latest edition, Mark Publishing Company, Easton, U.S.A.), together with pharmaceutically acceptable carriers and additives.
【００１６】[0016]
【実施例】以下、本発明に係る過酸化脂質抑制剤を用い
た実施例について説明するが、本発明の技術的範囲は、
これらの実施例に限定されるものではない。 〔実施例１〕過酸化脂質抑制剤の調製 本例では、以下の組成に従って複数種類のハーブを混合
して過酸化脂質抑制剤を調製した。 タイム …10重量％ ローズマリー …10重量％ ウコン …10重量％ フェンネル …10重量％ グレープ種子 …10重量％ シルクペプチド …10重量％ 簿公英 …10重量％ エゾウコギ …30重量％EXAMPLES Hereinafter, examples using the lipid peroxide inhibitor according to the present invention will be described, but the technical scope of the present invention is as follows.
It is not limited to these examples. [Example 1] Preparation of lipid peroxide inhibitor In this example, a plurality of herbs were mixed according to the following composition to prepare a lipid peroxide inhibitor. Thyme… 10% by weight Rosemary… 10% by weight Turmeric… 10% by weight Fennel… 10% by weight Grape seeds… 10% by weight Silk peptide… 10% by weight Book Kouei… 10% by weight Ezokogi… 30% by weight
【００１７】過酸化脂質抑制剤を調製する際には、先
ず、上記各ハーブを水道水により洗浄し、160℃に設定
したスプレードライヤーで乾燥殺菌を行った。次に、上
記配合比となるように各ハーブを秤量し、Ｖ型混合器を
用いて混合した。次に、混合したハーブを、粉砕機（パ
ワーミルP-7型昭和化学機械工作社製）を用いて粉末状
に加工した。そして、粉末状にした混合ハーブを打錠機
（（株）畑製作所 製）を用いて錠剤に成形することに
よって、過酸化脂質抑制剤を調製した。In preparing the lipid peroxide inhibitor, each herb was washed with tap water and dried and sterilized with a spray dryer set at 160 ° C. Next, each herb was weighed so that it might become the said mixing ratio, and it mixed using the V-type mixer. Next, the mixed herbs were processed into powder using a pulverizer (Power Mill Model P-7, manufactured by Showa Kagaku Kikai Kogyo). Then, the mixed herb in the form of a powder was formed into tablets using a tableting machine (manufactured by Hata Seisakusho) to prepare a lipid peroxide inhibitor.
【００１８】得られた過酸化脂質抑制剤を用いて酸化還
元電位を測定することによって、当該過酸化脂質抑制剤
の酸化還元能を検討した。本試験では、上述したように
得られた過酸化脂質抑制剤３ｇを水道水100ccに溶解し
たものを試料として使用した。そして、試料を２５℃に
維持した状態で、48時間の酸化還元電位の変化をORP計
RM-12P（東亜電波工業’（株） 製）を用いて測定し
た。「48時間」等の測定条件は体内の滞留時間を考慮し
たものである。測定結果を図１に示す。The redox potential of the lipid peroxide inhibitor was examined by measuring the redox potential using the obtained lipid peroxide inhibitor. In this test, a solution prepared by dissolving 3 g of the lipid peroxide inhibitor obtained as described above in 100 cc of tap water was used as a sample. Then, with the sample kept at 25 ° C., the change in oxidation-reduction potential for 48 hours was measured using an ORP meter.
The measurement was performed using RM-12P (manufactured by Toa Denpa Kogyo '). The measurement conditions such as “48 hours” take into account the residence time in the body. FIG. 1 shows the measurement results.
【００１９】図１から判るように、測定開始直後、試料
中の電位は+165mvであったが、48時間後に-212mvとなっ
ていた。このことから、過酸化脂質抑制剤を含む試料
は、時間経過と共に還元性が大きくなることがわかる。
したがって、過酸化脂質抑制剤を溶媒に溶解すると、時
間と共に電子が増加していることが明らかとなった。こ
の結果から、過酸化脂質抑制剤を体内に摂取すること
で、1）活性酸素による生体の酸化に寄与し、生体全体
を健全化する。2）ATPの合成を助け細胞を活性化するこ
とが示唆された。As can be seen from FIG. 1, the potential in the sample was +165 mv immediately after the start of the measurement, but was -212 mv after 48 hours. From this, it is understood that the sample containing the lipid peroxide inhibitor becomes more reducible with time.
Therefore, it became clear that when the lipid peroxide inhibitor was dissolved in the solvent, the number of electrons increased with time. From these results, ingestion of the lipid peroxide inhibitor into the body contributes to 1) oxidation of the living body by active oxygen, and makes the whole body sound. 2) It is suggested that ATP synthesis is activated and cells are activated.
【００２０】試験名Ａ この過酸化脂質抑制剤を用いて、Ｃｏｌｏｎ２６結腸癌
担癌モデルマウスの抗腫瘍効果試験を行った。Ｃｏｌｏ
ｎ２６結腸癌担癌モデルマウスは、日本クレア株式会社
から購入したＢＡＬＢ／Ｃ系統、雄、８週齢、微生物的
グレードがＳＰＦであるマウスを用いた。このマウスを
用いて、マウス結腸癌細胞株Ｃｏｌｏｎ２６を腹部皮下
投与にて移植したＣｏｌｏｎ２６坦癌マウスを作製し
た。マウス結腸癌細胞株Ｃｏｌｏｎ２６は、ＢＡＬＢ／
Ｃ系統のマウス直腸内にＮ−ｍｅｔｈｙ１−Ｎ−ｎｉｔ
ｒｏｓｏ−ｕｒｅｔａｎを繰り返し投与することにより
発生した癌細胞株に由来するものである。 Test Name A Using this lipid peroxide inhibitor, an antitumor effect test was conducted on a Colon 26 colon cancer-carrying model mouse. Colo
As the n26 colon cancer-carrying model mouse, a BALB / C strain purchased from CLEA Japan, male, 8 weeks old, and a microbial grade of SPF was used. Using this mouse, a Colon 26-carcinated mouse in which the mouse colon cancer cell line Colon 26 was transplanted by subcutaneous administration in the abdomen was prepared. The murine colon cancer cell line Colon 26 is BALB /
N-methyl1-N-nit is injected into the rectum of mouse strain C
It is derived from a cancer cell line generated by repeated administration of roso-uretan.
【００２１】そして、皮下移植２１日目のＣｏｌｏｎ２
６坦癌マウスより腫瘍部を摘出し、分離させた細胞を滅
菌生理食塩水に浮遊させ、癌細胞数を１×１０5／１０
０μｌ／匹として、6匹の上記マウスに対して腹部皮下
投与にて移植した。なお、マウスは以下の条件で飼育し
た。 設定温湿度；２４士１℃、６６士６％ 空調方式；７０％リターンエア方式 照明時間；１２時間自動点灯、消灯方式（午前８時〜午
後８時） 飼育設備；プラスチックケージ 飼料；固形飼料ＣＡ−１（日本クレア（株））を滅菌処
理 給水；蒸留水Then, Colon 2 on day 21 of subcutaneous transplantation
6 Tangan mice tumor section was excised from, was partitioned cells were suspended in sterilized physiological saline, the number of cancer cells 1 × 10 5/10
Six mice were implanted subcutaneously in the abdomen at 0 μl / mouse. The mice were bred under the following conditions. Set temperature / humidity; 24 ° C 1 ° C, 66 ° C 6% Air-conditioning system; 70% return air system Lighting time: 12 hours automatic light-on / light-off method (8 am to 8 pm) Breeding equipment; plastic cage feed; solid feed CA -1 (Clear Japan) sterilized water supply; distilled water
【００２２】本試験では、上記6匹のマウスのうち3匹を
対照群とし、3匹に対して過酸化脂質抑制剤を投与し
た。マウスに対しては、過酸化脂質抑制剤を蒸留水で溶
解したのち、胃ゾンデを用いて２００ｍｇ／ｋｇ用量を
１４日間連続経口法にて投与した。なお、対照群におい
ては蒸留水を投与した。過酸化脂質抑制剤の投与は、坦
癌マウスを作製した翌日より開始した。なお、癌細胞を
移植したマウスは、移植後から４日までは各群において
移植部位の肉眼及び触診による変化はみられなかった
が、６日以降からは癌細胞の増殖に伴う腹部皮膚の隆起
が確認されるようになった。１４日では削痩及び体毛の
立毛、腫瘍の大きな担癌マウスでは行動も不活発になり
うずくまりが観察された。In this test, three of the six mice were used as a control group, and three mice were administered a lipid peroxide inhibitor. After dissolving the lipid peroxide inhibitor in distilled water, the mice were administered a 200 mg / kg dose by oral route for 14 days using a gastric tube. In the control group, distilled water was administered. Administration of the lipid peroxide inhibitor was started on the day following the creation of the cancer mouse. The mice transplanted with the cancer cells did not show any change in the transplantation site by visual inspection and palpation in each group from day 4 after transplantation, but from day 6 onwards, the abdominal skin bulges due to the proliferation of the cancer cells. Began to be confirmed. On the 14th, slimming and squatting were observed in the tumor-bearing mice with large slimming and body hair and large tumors.
【００２３】飼育御１５日目に頸椎脱臼にて屠殺後、腫
瘍体積の測定並びにＩＬ−１２及びＴＮＦ−αの測定を
行った。腫瘍体積は、腫瘍径をノギス（プレートリーダ
Ｍ−２３００、ＮＵＮＫ社製）で測定し、腫瘍体積（ｍ
ｍ3）＝腫瘍の長径×短径2×０．４の数式に従って算出
した。ＩＬ−１２及びＴＮＦ−αは、摘出した脾臓を浮
遊細胞液とし、１０％ＦＣ８添加ＲＰＭＩ−１６４０培
地で細胞数を調整した後、２×１０8個／ｍ１あたりの
脾臓細胞にＣｏｎＡ５μｇ／ｍｌ加え、３７℃、５％Ｃ
Ｏ2インキュベータ（ＹＡＭＡＴＯ社製）内で２４時間
培養し、培養液の上清中に含まれるＩＬ−１２及びＴＮ
Ｆ−αをＣｙｔｅｓｃｒｅｅｎキット（ＢＩＯＳＯＵＲ
ＣＥ社製）を用いて測定した。なお、これらの実験を行
った際の施設環境は、７０％リターンエア方式の空調方
式を用いて、設定温度を２６±１℃とし、設定湿度を６
６±６％とした。On the 15th day of breeding, the mice were sacrificed by cervical dislocation, and the tumor volume and IL-12 and TNF-α were measured. The tumor volume was measured using a caliper (plate reader M-2300, manufactured by NUNK) and the tumor volume (m
m 3 ) = calculated according to the formula of tumor major axis × minor axis 2 × 0.4. IL-12 and TNF-α were prepared by using the excised spleen as a suspension cell solution, adjusting the cell number with RPMI-1640 medium supplemented with 10% FC8, and then adding 5 μg / ml of ConA to 2 × 10 8 spleen cells / ml. , 37 ° C, 5% C
The cells were cultured in an O 2 incubator (manufactured by YAMATO) for 24 hours, and IL-12 and TN contained in the supernatant of the culture solution were
F-α was transferred to Cytesscreen kit (BIOSOURCE
(Manufactured by CE). In addition, the facility environment at the time of performing these experiments was set to 26 ± 1 ° C. and a humidity of 6 using an air conditioning system of a 70% return air system.
6 ± 6%.
【００２４】過酸化脂質抑制剤を投与したマウス群（投
与群）と対照群とにおける腫瘍体積を比較した結果を図
２に示す。また、過酸化脂質抑制剤を投与したマウス群
（投与群）と対照群とにおけるＩＬ−１２濃度及びＴＮ
Ｆ−α濃度を比較した結果を図３に示す。FIG. 2 shows the results of comparison of tumor volume between the mouse group (administration group) to which the lipid peroxide inhibitor was administered and the control group. In addition, IL-12 concentration and TN in the mouse group (administration group) to which the lipid peroxide inhibitor was administered and the control group.
The result of comparing the F-α concentrations is shown in FIG.
【００２５】腫瘍体積の測定では、図２に示すように、
個体差がみられるものの平均値で対照群６２６．３８ｍ
ｍ3、過酸化脂質抑制剤投与群３３０．０２ｍｍ3であ
り、各群間に有意差が現れた。この結果から、過酸化脂
質抑制剤の投与によって、腫瘍体積増加抑制効果を確認
することができた。In the measurement of the tumor volume, as shown in FIG.
The average value of the control group was 626.38 m although individual differences were observed.
m 3 , which was 330.02 mm 3 , which was a significant difference between the groups. From these results, it was possible to confirm the effect of suppressing the increase in tumor volume by administering the lipid peroxide inhibitor.
【００２６】また、図３に示すように、アポトーシス誘
発因子であるＩＬ−１２においては対照群との有意差が
認められなかった。一方、腫瘍壊死因子であるＴＮＦ−
α濃度については、対照群２０．４５ｐｇ／ｍｌに対し
て、過酸化脂質抑制剤投与群３７．４６ｐｇ／ｍｌであ
り、各群間に有意差が現れた。この結果から、過酸化脂
質抑制剤の投与によって、Ｃｏｌｏｎ２６結腸担癌マウ
スに対してＴＮＦ−α産生能の上昇促進作用により腫瘍
増殖を抑制したものと推測された。Further, as shown in FIG. 3, no significant difference was observed in IL-12, which is an apoptosis-inducing factor, from the control group. On the other hand, TNF- which is a tumor necrosis factor
The α concentration was 37.46 pg / ml for the lipid peroxide inhibitor-administered group compared to 20.45 pg / ml for the control group, and a significant difference appeared between the groups. From these results, it was presumed that administration of the lipid peroxide inhibitor suppressed tumor growth in colon 26 colon cancer-bearing mice by promoting TNF-α production.
【００２７】試験名Ｂ 過酸化脂質抑制剤を用いて、有酸素運動時における血中
過酸化脂質濃度の変動を測定した。本試験では、供試動
物として、日本クレア株式会社から購入した12匹のラッ
トを用いた。これらラットは、ウィスタ系統のオスで、
１４週齢、微生物的グレードがＳＰＦである。 Test Name B Using a lipid peroxide inhibitor, the change in blood lipid peroxide concentration during aerobic exercise was measured. In this test, 12 rats purchased from CLEA Japan were used as test animals. These rats are Wistar males,
14 weeks old, microbiological grade is SPF.
【００２８】これらのラットを、以下の条件で3日間飼
育した。 設定温湿度；２４士１℃、６６士６％ 空調方式；７０％リターンエア方式 照明時間；１２時間自動点灯、消灯方式（午前８時〜午
後８時） 飼育設備；プラケットケージケージ 飼料；固形飼料ＣＡ−１（日本クレア（株））を滅菌処
理 給水；フィルターろ過した水道水These rats were bred for 3 days under the following conditions. Set temperature / humidity: 24 ° C 1 ° C, 66 ° C 6% Air-conditioning method; 70% return air method Lighting time: 12 hours automatic lighting, turn-off method (8:00 am to 8:00 pm) Breeding equipment; placket cage cage Feed; solid feed Sterilization treatment of CA-1 (CLEA Japan) Water supply: Tap water filtered
【００２９】本試験では、上記１２匹のマウスのうち６
匹を対照群とし、６匹に対して過酸化脂質抑制剤を投与
した。ラットに対しては、過酸化脂質抑制剤を蒸留水で
溶解したのち、胃ゾンデを用いて２００ｍｇ／ｋｇ用量
を３日間連続経口法にて投与した。なお、対照群におい
ては蒸留水を投与した。In this test, 6 out of the 12 mice were used.
The animals were set as a control group, and six animals were administered a lipid peroxide inhibitor. After dissolving the lipid peroxide inhibitor in distilled water, rats were administered a 200 mg / kg dose by a continuous oral method using a gastric tube for 3 days. In the control group, distilled water was administered.
【００３０】3日間の飼育後、トレッドミル（ＳＮ−４
６０、株式会社シナノ製作所社製）の走行速度を２３ｍ
／ｍｉｎとして２０分間の有酸素運動を実施した。この
有酸素運動直後と30分経過後とにおける、血中過酸化脂
質濃度を測定した。すなわち、両群ともに、有酸素運動
終了直後において3匹のラットから採血し、有酸素運動
終了30分後において他の3匹のラットから採血し、血中
過酸化脂質濃度を測定した。After breeding for 3 days, the treadmill (SN-4)
60, manufactured by Shinano Manufacturing Co., Ltd.)
Aerobic exercise for 20 minutes was carried out at a rate of / min. Blood lipid peroxide levels were measured immediately after the aerobic exercise and after 30 minutes. That is, in both groups, blood was collected from three rats immediately after the end of the aerobic exercise, and blood was collected from the other three rats 30 minutes after the end of the aerobic exercise, and the blood lipid peroxide concentration was measured.
【００３１】採血は、麻酔下において解剖し、腹大動脈
より行った。血中過酸化脂質濃度は、採血した血液から
血漿を測定試料として抽出し、この測定試料からＴＢＡ
−蛍光法を用いて血中過酸化脂質濃度を測定した。過酸
化脂質抑制剤を投与したマウス群（投与群）と対照群と
における血中過酸化脂質濃度を比較した結果を図４に示
す。Blood samples were dissected under anesthesia and taken from the abdominal aorta. The concentration of lipid peroxide in blood is determined by extracting plasma as a measurement sample from collected blood,
-The concentration of lipid peroxide in blood was measured using a fluorescence method. FIG. 4 shows the results of comparison of the blood lipid peroxide concentration between the mouse group (administration group) to which the lipid peroxide inhibitor was administered and the control group.
【００３２】血中の過酸化脂質濃度は、図４に示すよう
に、対照群において運動負荷直後３．３ｍｏｌ／ｍｌ、
運動負荷３０分後では４．４ｍｏｌ／ｍｌであるのに対
し、過酸化脂質抑制剤投与群では運動負荷直後２．０ｍ
ｏｌ／ｍｌ、運動負荷３０分後では２．２ｍｏｌ／ｍｌ
であり、各群間に有意差が現れた。この結果から、過酸
化脂質抑制剤の投与によって、有酸素運動負荷時に発生
する過酸化脂質を抑制できること確認することができ
た。As shown in FIG. 4, the blood lipid peroxide concentration in the control group was 3.3 mol / ml immediately after exercise load,
After 30 minutes from the exercise load, the concentration was 4.4 mol / ml, whereas in the lipid peroxide inhibitor administration group, 2.0 m immediately after the exercise load.
ol / ml, 2.2 mol / ml after 30 minutes of exercise load
And a significant difference appeared between the groups. From these results, it was confirmed that administration of the lipid peroxide inhibitor can suppress lipid peroxide generated during aerobic exercise.
【００３３】試験名Ｃ 過酸化脂質抑制剤を用いて、ストレス負荷時における血
中過酸化脂質濃度の変動を測定した。本試験では、試験
名Ｂで用いたラットと同し飼育条件とし、試験名Ｂにお
ける有酸素運動と異なり、エアージェットストレスを負
荷した。エアージェットストレスは、試験名Ｂと同様に
3日間飼育した後、3000Ｗのドライヤーを用いて20分間
行った。なお、本試験においても、12匹のラットを使用
し、そのうち6匹を対照群とし、残りの6匹に対して過酸
化脂質抑制剤を投与した。 Test Name C Using a lipid peroxide inhibitor, the change in blood lipid peroxide concentration under stress was measured. In this test, the rats were kept under the same breeding conditions as the rats used in Test Name B, and air jet stress was applied unlike the aerobic exercise in Test Name B. Air jet stress is the same as test name B
After breeding for 3 days, it was carried out for 20 minutes using a 3000 W dryer. In this test also, 12 rats were used, 6 of which were used as a control group, and the remaining 6 rats were administered a lipid peroxide inhibitor.
【００３４】このエアージェットストレス直後と30分経
過後とにおける、血中過酸化脂質濃度を測定した。すな
わち、両群ともに、エアージェットストレス終了直後に
おいて3匹のラットから採血し、エアージェットストレ
ス終了30分後において他の3匹のラットから採血し、血
中過酸化脂質濃度を測定した。試験名Ｂと同様にして血
中過酸化脂質濃度を測定した結果を図４に示す。The blood lipid peroxide concentration was measured immediately after the air jet stress and after 30 minutes. That is, in both groups, blood was collected from three rats immediately after the end of the air jet stress, and blood was collected from the other three rats 30 minutes after the end of the air jet stress, and the blood lipid peroxide concentration was measured. The result of measuring the blood lipid peroxide concentration in the same manner as in Test Name B is shown in FIG.
【００３５】図５に示すように、血中過酸化脂質濃度の
変動は、対照群においてストレス負荷直後１．８ｎｍｏ
ｌ／ｍｌ、ストレス負荷３０分後では２．６ｎｍｏｌ／
ｍｌであるのに対し、過酸化脂質抑制剤投与群ではスト
レス負荷直後０．９ｎｍｏｌ／ｍｌ、ストレス負荷３０
分後では１．２ｎｍｏｌ／ｍｌであり、各群間に有意差
が現れた。この結果から、過酸化脂質抑制剤の投与によ
って、ストレス負荷時に発生する過酸化脂質を抑制でき
ること確認することができた。As shown in FIG. 5, the change in blood lipid peroxide concentration was 1.8 nmo immediately after the stress load in the control group.
l / ml, 2.6 nmol / after 30 minutes of stress loading
In the group administered with the lipid peroxide inhibitor, 0.9 nmol / ml immediately after stress loading, and
One minute later, it was 1.2 nmol / ml, and a significant difference appeared between the groups. From these results, it was confirmed that administration of the lipid peroxide inhibitor could suppress lipid peroxide generated during stress load.
【００３６】[0036]
【発明の効果】以上、詳細に説明したように、本発明に
係る過酸化脂質抑制剤は、複数種類のハーブを混合して
なり、イオン交換能を有する混合ハーブを有効成分とし
て含むため、体内に蓄積した過酸化脂質を抑制すること
ができる。したがって、この過酸化脂質抑制剤によれ
ば、過酸化脂質の蓄積に起因する症状、例えば、白血球
数の低下や脱毛といった症状を改善することができる。As described above in detail, the lipid peroxide inhibitor according to the present invention is obtained by mixing a plurality of types of herbs, and contains a mixed herb having ion exchange ability as an active ingredient. Lipid peroxide accumulated in the cell can be suppressed. Therefore, according to the lipid peroxide inhibitor, symptoms caused by accumulation of lipid peroxide, for example, symptoms such as a decrease in the number of white blood cells and hair loss can be improved.
【図１】過酸化脂質抑制剤の酸化還元電位の経時変化を
示す特性図である。FIG. 1 is a characteristic diagram showing a change with time of the oxidation-reduction potential of a lipid peroxide inhibitor.
【図２】過酸化脂質抑制剤投与群と対照群とにおける腫
瘍体積を示す特性図である。FIG. 2 is a characteristic diagram showing tumor volumes in a lipid peroxide inhibitor-administered group and a control group.
【図３】過酸化脂質抑制剤投与群と対照群とにおけるＩ
Ｌ−１２濃度及びＴＨＦ−α濃度を示す特性図である。FIG. 3 shows I in a lipid peroxide inhibitor-administered group and a control group.
It is a characteristic view which shows L-12 density | concentration and THF- (alpha) density | concentration.
【図４】有酸素運動時の血中過酸化脂質濃度の変化を示
す特性図である。FIG. 4 is a characteristic diagram showing a change in blood lipid peroxide concentration during aerobic exercise.
【図５】ストレス負荷時の血中過酸化脂質濃度の変化を
示す特性図である。FIG. 5 is a characteristic diagram showing a change in blood lipid peroxide concentration during a stress load.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 ＦＩ テーマコート゛(参考） Ａ６１Ｐ 7/00 Ａ６１Ｐ 17/14 17/14 31/16 31/16 35/00 35/00 Ａ６１Ｋ 37/12 Ｆターム(参考） 4C084 AA02 BA44 CA49 DC23 MA35 MA52 NA06 NA14 ZA511 ZA922 ZB261 ZB331 ZC332 ZC522 ZC541 ZC751 4C088 AB16 AB26 AB38 AB56 AB81 AC04 AC05 AD09 BA07 CA19 MA02 MA07 MA35 MA52 NA06 NA14 ZA51 ZA92 ZB26 ZB33 ZC33 ZC52 ZC54 ZC75 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI theme coat ゛ (reference) A61P 7/00 A61P 17/14 17/14 31/16 31/16 35/00 35/00 A61K 37/12 F-term (reference) 4C084 AA02 BA44 CA49 DC23 MA35 MA52 NA06 NA14 ZA511 ZA922 ZB261 ZB331 ZC332 ZC522 ZC541 ZC751 4C088 AB16 AB26 AB38 AB56 AB81 AC04 AC05 AD09 BA07 CA19 MA02 MA07 MA35 MA52 NA06 NA14 ZA51 ZA92 Z33 Z33
Claims (3)
を有する混合ハーブを有効成分として含む過酸化脂質抑
制剤。1. A lipid peroxide inhibitor comprising, as an active ingredient, a mixed herb having ion exchange ability, which contains a plurality of kinds of herbs.
せることを特徴とする請求項１記載の過酸化脂質抑制
剤。2. The lipid peroxide inhibitor according to claim 1, which generates electrons of -200 mV or less in the body.
ー、ウコン、フェンネル、グレープ種子、シルクペプチ
ド、蒲公英及びエゾウコギから選ばれる少なくとも１種
以上からなることを特徴とする請求項１記載の過酸化脂
質抑制剤。3. The lipid peroxide according to claim 1, wherein the mixed herb comprises at least one member selected from thyme, rosemary, turmeric, fennel, grape seed, silk peptide, Gong Kim and Eleuthero. Inhibitors.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000335960A JP2002145789A (en) | 2000-11-02 | 2000-11-02 | Lipid peroxide inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000335960A JP2002145789A (en) | 2000-11-02 | 2000-11-02 | Lipid peroxide inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002145789A true JP2002145789A (en) | 2002-05-22 |
Family
ID=18811617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000335960A Pending JP2002145789A (en) | 2000-11-02 | 2000-11-02 | Lipid peroxide inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2002145789A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2937538A1 (en) * | 2008-10-23 | 2010-04-30 | Muselier Corinne Treger | ANTIGRIPPAL PRODUCT |
| JP2013076692A (en) * | 2011-09-13 | 2013-04-25 | Taisho Pharmaceutical Co Ltd | Method for determining fatigue with use of oxidized phospholipid |
| CN104825899A (en) * | 2015-05-29 | 2015-08-12 | 合肥丰瑞隆生物科技有限公司 | Traditional Chinese medicine for treating lung cancer |
| CN104857447A (en) * | 2015-05-29 | 2015-08-26 | 合肥丰瑞隆生物科技有限公司 | Traditional Chinese medicine for treating intestinal cancer |
| CN105056136A (en) * | 2015-08-24 | 2015-11-18 | 济南邦文医药科技有限公司 | Traditional Chinese medicine composition for treating non-small-cell lung cancer hypercoagulability |
| CN105148124A (en) * | 2015-08-24 | 2015-12-16 | 南京中医药大学 | Composition with anti-tumor function and application thereof |
| CN105213884A (en) * | 2015-10-19 | 2016-01-06 | 青岛市中心医院 | A kind of pharmaceutical composition and application thereof for the treatment of colon cancer |
| CN105213840A (en) * | 2015-10-19 | 2016-01-06 | 青岛市中心医院 | A kind of pharmaceutical composition and application thereof for the treatment of nasopharyngeal carcinoma |
-
2000
- 2000-11-02 JP JP2000335960A patent/JP2002145789A/en active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2937538A1 (en) * | 2008-10-23 | 2010-04-30 | Muselier Corinne Treger | ANTIGRIPPAL PRODUCT |
| WO2010046572A3 (en) * | 2008-10-23 | 2010-07-22 | Corinne Treger | Anti-influenza device and composition containing extracts from olive tree leaves, grapefruit pips, rosemary, green tea and curcumin |
| JP2013076692A (en) * | 2011-09-13 | 2013-04-25 | Taisho Pharmaceutical Co Ltd | Method for determining fatigue with use of oxidized phospholipid |
| CN104825899A (en) * | 2015-05-29 | 2015-08-12 | 合肥丰瑞隆生物科技有限公司 | Traditional Chinese medicine for treating lung cancer |
| CN104857447A (en) * | 2015-05-29 | 2015-08-26 | 合肥丰瑞隆生物科技有限公司 | Traditional Chinese medicine for treating intestinal cancer |
| CN105056136A (en) * | 2015-08-24 | 2015-11-18 | 济南邦文医药科技有限公司 | Traditional Chinese medicine composition for treating non-small-cell lung cancer hypercoagulability |
| CN105148124A (en) * | 2015-08-24 | 2015-12-16 | 南京中医药大学 | Composition with anti-tumor function and application thereof |
| CN105213884A (en) * | 2015-10-19 | 2016-01-06 | 青岛市中心医院 | A kind of pharmaceutical composition and application thereof for the treatment of colon cancer |
| CN105213840A (en) * | 2015-10-19 | 2016-01-06 | 青岛市中心医院 | A kind of pharmaceutical composition and application thereof for the treatment of nasopharyngeal carcinoma |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Einhorn | Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture | |
| EA015922B1 (en) | Administration of mtor inhibitor to treat patients with cancer | |
| Wang et al. | RA-XII, a bicyclic hexapeptidic glucoside isolated from Rubia yunnanensis Diels, exerts antitumor activity by inhibiting protective autophagy and activating Akt-mTOR pathway in colorectal cancer cells | |
| US6063814A (en) | Phorbol esters as anti-neoplastic and white blood cell elevating agents | |
| RU2014124171A (en) | MEDICINE FOR THERAPEUTIC TREATMENT AND / OR IMPROVEMENT OF SEPSIS | |
| Wei et al. | Urolithin A attenuates RANKL-induced osteoclastogenesis by co-regulating the p38 MAPK and Nrf2 signaling pathway | |
| JP2002145789A (en) | Lipid peroxide inhibitor | |
| EP0235151B1 (en) | Proglumide and pharmaceutical compositions containing it for use in the treatment of neoplastic affections | |
| Chen et al. | Oxalate as a potent promoter of kidney stone formation | |
| Li-Li et al. | 5, 7, 2’, 4’, 5’-Pentamethoxyflavanone regulates M1/M2 macrophage phenotype and protects the septic mice | |
| CN109730983A (en) | Application of the rhapontigenin in preparation treatment medication for treating pyemia | |
| JPS60501408A (en) | Methods and agents for increasing animal tolerance to oxidant stress-inducing antibiotics | |
| US11167002B2 (en) | Pharmaceutical composition for the treatment of malignant neoplasms including sarcoma, cancers of liver, lung, bladder, blood and cervical, treatment of infectious diseases and type 2 diabetes | |
| CN111939159A (en) | Application of NSC23766 in tumor radiotherapy assisting | |
| CN111714500A (en) | Pharmaceutical composition containing naringenin and application thereof in treating colorectal cancer | |
| CN111714483A (en) | Use of cysteine derivatives as radioprotectors | |
| Uemura et al. | The protective effect of interleukin-11 on the cell death induced by X-ray irradiation in cultured intestinal epithelial cell | |
| CN115708823B (en) | Application of ursin in preparation of medicines for preventing and/or treating sepsis lung injury | |
| KR102063397B1 (en) | Compositions for preventing or treating lung cancer or colon cancer comprising PFI-3 | |
| CN111195250A (en) | Application of combination of cydapamide and DICE and combined medicine | |
| Lin et al. | Auranofin and ICG-001 emerge synergistic anti-tumor effect on canine breast cancer by inducing apoptosis via mitochondrial pathway | |
| CN117482049B (en) | An antitumor composition | |
| CN115137831B (en) | Application of astaxanthin in preparation of anti-angiogenesis drug synergist and pharmaceutical composition | |
| CN115177620A (en) | Application of seolonide or pharmaceutically acceptable salt thereof in preparation of medicine for preventing or treating follicular lymphoma | |
| CN104117064A (en) | Combined application of isothiocyanate compound and hormone medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070724 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071120 |